美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响(1)
[摘要]目的 探討美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响。方法 选取2016年7月～2018年6月九江市第一人民医院心内科收治的104例冠心病心力衰竭患者作为研究对象，按照随机数字表法分为对照组(52例)和观察组(52例)。对照组采用美托洛尔治疗，观察组采用美托洛尔联合曲美他嗪治疗。比较两组的临床治疗效果、治疗前后的炎症因子水平和心功能指标及不良反应总发生率。结果 观察组的治疗总有效率高于对照组，差异有统计学意义(P<0.05)。两组治疗后的肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平低于治疗前，观察组治疗后的TNF-α、IL-6和hs-CRP水平低于对照组，差异均有统计学意义(P<0.05)。两组治疗后的左室射血分数(LVEF)高于治疗前，左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)低于治疗前，观察组治疗后的LVEF高于对照组，LVESD、LVEDD低于对照组，差异均有统计学意义(P<0.05)。两组的不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 冠心病心力衰竭患者行美托洛尔联合曲美他嗪治疗可有效提高治疗效果，改善心功能，降低炎症因子水平，值得临床推广应用。
[关键词]冠心病心力衰竭;美托洛尔;曲美他嗪;炎症因子;心功能
[中图分类号] R541.4 [文献标识码] A [文章编号] 1674-4721(2020)3(a)-0048-04
Effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure
TANG Zeng-yao LIU Ji-wen WANG Xin-wang ZHU Bao-cheng LIU Yu-lian
Department of Internal Medicine Cardiology， Jiujiang First People′s Hospital of Jiangxi Province， Jiujiang 332000， China
[Abstract] Objective To investigate the effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods A total of 104 patients with coronary heart disease and heart failure who were admitted to the Department of Cardiology， Jiujiang First People′s Hospital from July 2016 to June 2018 were selected as the research objects， they were divided into control group (52 cases) and observation group (52 cases) according to the random number table method. The control group was treated with Metoprolol， and the observation group was treated with Metoprolol combined with Trimetazidine. The clinical treatment effect， inflammatory factor levels and cardiac function indexes before and after treatment， and total incidence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group， the difference was statistically significant (P<0.05). The levels of tumor necrosis factor-α (TNF-α)， interleukin-6 (IL-6)， and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment were lower than those before treatment， the levels of TNF-α， IL-6 and hs-CRP in the observation group after treatment were lower than those in the control group， the differences were statistically significant (P<0.05). After treatment， the left ventricular ejection fraction (LVEF) in the two groups was higher than that before treatment， the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were lower than those before treatment， the LVEF after treatment in the observation group was higher than that in the control group， and LVESD and LVEDD were lower than those in the control group， the differences were statistically significant (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of patients with coronary heart disease and heart failure with Metoprolol combined with Trimetazidine can effectively improve the treatment effect， improve cardiac function， and reduce the level of inflammatory factors， which is worthy of clinical application., 百拇医药(汤曾耀 刘继文 王新旺 朱保成 刘玉连)
[关键词]冠心病心力衰竭;美托洛尔;曲美他嗪;炎症因子;心功能
[中图分类号] R541.4 [文献标识码] A [文章编号] 1674-4721(2020)3(a)-0048-04
Effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure
TANG Zeng-yao LIU Ji-wen WANG Xin-wang ZHU Bao-cheng LIU Yu-lian
Department of Internal Medicine Cardiology， Jiujiang First People′s Hospital of Jiangxi Province， Jiujiang 332000， China
[Abstract] Objective To investigate the effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods A total of 104 patients with coronary heart disease and heart failure who were admitted to the Department of Cardiology， Jiujiang First People′s Hospital from July 2016 to June 2018 were selected as the research objects， they were divided into control group (52 cases) and observation group (52 cases) according to the random number table method. The control group was treated with Metoprolol， and the observation group was treated with Metoprolol combined with Trimetazidine. The clinical treatment effect， inflammatory factor levels and cardiac function indexes before and after treatment， and total incidence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group， the difference was statistically significant (P<0.05). The levels of tumor necrosis factor-α (TNF-α)， interleukin-6 (IL-6)， and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment were lower than those before treatment， the levels of TNF-α， IL-6 and hs-CRP in the observation group after treatment were lower than those in the control group， the differences were statistically significant (P<0.05). After treatment， the left ventricular ejection fraction (LVEF) in the two groups was higher than that before treatment， the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were lower than those before treatment， the LVEF after treatment in the observation group was higher than that in the control group， and LVESD and LVEDD were lower than those in the control group， the differences were statistically significant (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of patients with coronary heart disease and heart failure with Metoprolol combined with Trimetazidine can effectively improve the treatment effect， improve cardiac function， and reduce the level of inflammatory factors， which is worthy of clinical application., 百拇医药(汤曾耀 刘继文 王新旺 朱保成 刘玉连)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 心力衰竭